Zhejiang Jiuzhou Pharmaceutical Co Ltd

Zhejiang Jiuzhou Pharmaceutical Co Ltd (Jiuzhou Pharma) is a prominent player in the pharmaceutical industry, specialising in the research and development, production, and sale of active pharmaceutical ingredients (APIs). The company is renowned for its one-stop contract development and manufacturing (CDMO) services, catering to global pharmaceutical giants across Asia, Europe, and North America. Established in 1998 and listed on the Shanghai Stock Exchange in 2014, Jiuzhou Pharma has emerged as a leading manufacturer and supplier of key APIs such as Carbamazepine, Sulfasalazine, Ketoprofen, and Gliclazide worldwide. With a robust infrastructure comprising seven API plants, two finished dosage form (FDF) manufacturing bases, and three R&D centres in China and the USA, the company is at the forefront of small molecule API, intermediate, peptide, and FDF production. Their expertise encompasses key technologies including chiral synthesis, fluorine chemistry, flow chemistry, and bio-catalysis, all underpinned by well-established quality systems compliant with cGMP and recognised by global regulatory authorities.

Services include:
- Contract Development and Manufacturing (CDMO)
- Intermediates
- Fine Chemicals

Zhejiang Jiuzhou Pharmaceutical Co Ltd continues to uphold a commitment to quality and innovation, ensuring compliance with first-class environmental, health, and safety management systems, as well as intellectual property protection programmes. For further information, please visit jiuzhoupharma.com.

Type of Drugs Manufactured:

Small Molecule

Peptides

CDMO Services:

Drug Substance Manufacturing (API);Drug Product Formulation (FDF);Research & Development;Analytical Development

No. of Manufacturing Facilities:

More than 10

High Potent Products capabilities:

OEB 3;OEB 4-5

Facilities Locations:

Europe;North America;China;East Asia

Regulatory Approvals for your facilities:

FDA (United States);EMA (Europe);ISO;GMP